A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
NCT01121549
·
clinicaltrials.gov ↗
TERMINATED
Status
378
Enrollment
INDUSTRY
Sponsor class
Stopped
See termination reason in detailed description.
Conditions
Invasive Early Breast Cancer
Interventions
DRUG:
Aromasin
Sponsor
Pfizer